Talphera (TLPH) Non-Current Debt (2011 - 2023)
Talphera (TLPH) posted Non-Current Debt of $3.3 million for Q1 2023, up 8.52% on a QoQ basis from $3.0 million in Q1 2022, and up 8.52% year-over-year from $3.0 million in Q1 2022.
Analysis
Talphera (TLPH) Non-Current Debt (2011 - 2023) Analysis & Trends
Talphera has reported Non-Current Debt for 13 years, with the latest figure at $3.3 million in Q1 2023.
- On a quarterly basis, Non-Current Debt rose 8.52% year-over-year to $3.3 million in Q1 2023; TTM through Mar 2023 was $3.3 million, a 8.52% increase from a year earlier, with the FY2021 full-year figure at $5.0 million, down 61.89% from the prior year.
- Non-Current Debt was $3.3 million for Q1 2023 at Talphera, up from $3.0 million in the prior quarter.
- The five-year high for Non-Current Debt was $23.8 million in Q2 2019, with the low at $3.0 million in Q1 2022.
- Average Non-Current Debt over 5 years is $13.1 million, with a median of $13.1 million recorded in 2020.
- The sharpest annual moves came in 2019 and 2022: Non-Current Debt jumped 507.01% in 2019, then sank 73.0% in 2022.
- Over 5 years, Non-Current Debt stood at $20.5 million in 2019, then slumped by 35.96% to $13.1 million in 2020, then plunged by 61.89% to $5.0 million in 2021, then slumped by 39.27% to $3.0 million in 2022, then climbed by 8.52% to $3.3 million in 2023.
- The last three Non-Current Debt figures came in at $3.3 million (Q1 2023), $3.0 million (Q1 2022), and $5.0 million (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 3.30 Mn |
| Mar 31, 2022 | 3.04 Mn |
| Dec 31, 2021 | 5.01 Mn |
| Sep 30, 2021 | 6.95 Mn |
| Jun 30, 2021 | 9.37 Mn |
| Mar 31, 2021 | 11.27 Mn |
| Dec 31, 2020 | 13.14 Mn |
| Sep 30, 2020 | 14.99 Mn |
| Jun 30, 2020 | 17.32 Mn |
| Mar 31, 2020 | 19.13 Mn |
| Dec 31, 2019 | 20.52 Mn |
| Sep 30, 2019 | 21.92 Mn |
| Jun 30, 2019 | 23.77 Mn |
| Dec 31, 2018 | 3.38 Mn |
| Sep 30, 2018 | 5.50 Mn |
| Jun 30, 2018 | 7.54 Mn |
| Mar 31, 2018 | 9.49 Mn |
| Dec 31, 2017 | 11.37 Mn |
| Sep 30, 2017 | 13.15 Mn |
| Jun 30, 2017 | 14.89 Mn |